

CXCL13 Is a Biomarker of Anti-Leucine-Rich Glioma-Inactivated Protein I Encephalitis Patients [Response to Letter]

This article was published in the following Dove Press journal:
Neuropsychiatric Disease and Treatment

Sheng-jun Wang
Xue-wu Liu

Department of Neurology, Qilu Hospital,
Shandong University, Ji'nan, People's
Republic of China

Dear editor

Thanks for the concerns and comments of Mr. Zuowei Duan. There were indeed some limitations in our published article since it was only a preliminary exploratory research. As for the rarity of LGII encephalitis, only sixteen patients were enrolled in our study. The multifactorial analysis of variance was hard to be evaluated. But we do believe the statistical significance of our finding about the increasing of CXCL13 levels in the patients.

We agree that the clinical significance of CXCL13 levels increasing should not be over-estimated by clinicians. We have stated that the increasing of CXCL13 levels were reported in other autoimmune diseases including multiple sclerosis, neuroborreliosis and anti-NMDAR encephalitis in "Discussion Section" of our published article. The specificity and sensitivity of CXCL13 in serum/CSF for autoimmune encephalitis still need to be further investigated. Anyhow, we have found a potential biomarker for the diagnosis of anti-LGII encephalitis.

Disclosure

The authors report no conflicts of interest in this communication.

Correspondence: Sheng-jun Wang; Xue-wu Liu
Department of Neurology, Qilu Hospital,
Shandong University, 107# Wen Hua Xi
Road, Ji'nan 250012, People's Republic of
China
Email junwang9999@sina.com;
qiluliyum66@163.com

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Neuropsychiatric Disease and Treatment 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Neuropsychiatric Disease and Treatment editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Neuropsychiatric Disease and Treatment

Dovepress

Publish your work in this journal

Neuropsychiatric Disease and Treatment is an international, peer-reviewed journal of clinical therapeutics and pharmacology focusing on concise rapid reporting of clinical or pre-clinical studies on a range of neuropsychiatric and neurological disorders. This journal is indexed on PubMed Central, the 'PsycINFO' database and CAS, and

is the official journal of The International Neuropsychiatric Association (INA). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal>